Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/8/2024 | $90.00 → $89.00 | Underweight → Neutral | JP Morgan |
| 4/11/2024 | $100.00 → $112.00 | Equal Weight → Overweight | Wells Fargo |
| 3/14/2024 | $100.00 → $126.00 | Hold → Buy | Jefferies |
| 3/1/2024 | $108.00 | Outperform | Wolfe Research |
| 6/29/2023 | Outperform → In-line | Evercore ISI | |
| 6/26/2023 | $109.00 → $90.00 | Outperform → Market Perform | BMO Capital Markets |
| 2/2/2023 | $104.00 → $105.00 | Neutral → Underweight | JP Morgan |
| 9/12/2022 | $120.00 | Outperform | Credit Suisse |
DEFA14A - ASHLAND INC. (0001674862) (Filer)
DEF 14A - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
JP Morgan upgraded Ashland from Underweight to Neutral and set a new price target of $89.00 from $90.00 previously
Wells Fargo upgraded Ashland from Equal Weight to Overweight and set a new price target of $112.00 from $100.00 previously
Jefferies upgraded Ashland from Hold to Buy and set a new price target of $126.00 from $100.00 previously
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio
WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024. Prior to Celanese, Kulkarni held leadership positions at United Te
Wilmington, Del., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has signed a definitive agreement to sell its Avoca business to Mane. The transaction is expected to close in the calendar first quarter 2025, subject to the satisfaction of customary closing conditions. Ashland's Avoca business supplies Sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space with a dedicated team and attrac
Accomplished chemical industry CFO brings substantial finance and capital management expertise and experience driving corporate transformation Ingevity Corporation (NYSE:NGVT) today announced the election of J. Kevin Willis to the board of directors effective today. With Mr. Willis's election, the Board now includes nine directors, eight of whom are independent. Mr. Willis is senior vice president and chief financial officer (CFO) at Ashland Inc. (NYSE:ASH), a global additives and specialty ingredients company serving a wide range of consumer and industrial markets, including architectural coatings, automotive, construction, energy, food and beverage, nutraceuticals, personal care and p
Wilmington, Del., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Participating in a tradition that has evolved since 1792, today, employees from Ashland Inc. (NYSE:ASH) gathered on the floor of the New York Stock Exchange as Guillermo Novo, chair and chief executive officer, Ashland, joined by company executives, rang the trading day's opening bell. The event signifies a decade of evolution, resilience and sustainable solutions for the additives and specialty ingredients company and recognizes its 100-year anniversary. "I want to thank our employees for their dedication, our customers for their trust and our shareholders for their support over the years which continues to be the foundation of our suc
4 - ASHLAND INC. (0001674862) (Issuer)
4/A - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
WILMINGTON, Del., Nov. 14, 2024 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on December 15, 2024, to stockholders of record at the close of business on December 1, 2024. As of October 31, 2024, there were 47,109,326 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coa
Financial results for fourth-quarter fiscal 20241 Sales of $522 million, up one percent from the prior-year quarterSold nutraceuticals business to Turnspire Capital Partners LLCPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives reduced overall sales by approximately $24 million or five percent versus the prior-year quarterIncome from continuing operations of $19 million, or $0.39 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $61 million, or $1.26 per diluted shareAdjusted EBITDA of $124 million, up 68 percent from the prior-year quarterAdjusted EBITDA below
WILMINGTON, Del., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) today announced plans to issue its fourth-quarter fiscal 2024 earnings release at approximately 5 p.m. ET on Wednesday, November 6, 2024. The company's live webcast with securities analysts will include an executive summary and detailed remarks. The live webcast will take place at 9 a.m. ET on Thursday, November 7. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. Among those participating in the webcast presentation will be: Guillermo Novo, chair, and chief executive officerKevin Willis, senior vice president and chief fin
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND INC. (0001674862) (Subject)